2月27日 - ** Moderna MRNA.O股价盘前下跌3.28%，至32.48美元
** 彭博新闻社（(link)）周三援引消息人士的话报导称，美国卫生官员正在重新评估一份价值5.9亿美元的合同，该合同是授予co公司用于开发禽流感疫苗的。
** 该报导补充说，审查是政府推动检查基于信使 RNA 的疫苗支出的一部分，Moderna 公司的 COVID 疫苗就是采用了这种技术。
** 美国政府今年 1 月向 (link) MRNA 公司拨款 5.9 亿美元，用于推进其禽流感疫苗的开发。
** 股价在过去 12 个月中下跌了近 65
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.